These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34667075)

  • 1. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
    Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
    CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019.
    Clopper BR; Zhou Y; Tannis A; Staat MA; Rice M; Boom JA; Sahni LC; Selvarangan R; Harrison CJ; Halasa NB; Stewart LS; Weinberg GA; Szilagyi PG; Klein EJ; Englund JA; Rha B; Lively JY; Ortega-Sanchez IR; McMorrow ML; Moline HL
    J Pediatr; 2024 Aug; 271():114045. PubMed ID: 38561048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya.
    Nyiro JU; Nyawanda BO; Mutunga M; Murunga N; Nokes DJ; Bigogo G; Otieno NA; Lidechi S; Mazoya B; Jit M; Cohen C; Moyes J; Pecenka C; Baral R; Onyango C; Munywoki PK; Vodicka E
    BMC Public Health; 2024 Sep; 24(1):2410. PubMed ID: 39232690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilisation and costs in infants with confirmed respiratory syncytial virus infections: a national population cohort study.
    Han HJ; Ryu D; Kim JY; Jang S; Suh HS
    BMC Infect Dis; 2024 Oct; 24(1):1152. PubMed ID: 39396944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
    Mac S; Shi S; Millson B; Tehrani A; Eberg M; Myageri V; Langley JM; Simpson S
    Vaccine; 2023 Aug; 41(35):5141-5149. PubMed ID: 37422377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of disease and cost of illness of infants less than 6 months of age hospitalised with respiratory syncytial virus in Denmark - a 10-year national register-based study.
    von Linstow ML; Rudolfsen JH; Olsen J; Skovdal M; Staerke NB
    BMC Infect Dis; 2024 Oct; 24(1):1098. PubMed ID: 39363313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inpatient burden of respiratory syncytial virus (RSV) in Switzerland, 2003 to 2021: an analysis of administrative data.
    Stucki M; Lenzin G; Agyeman PK; Posfay-Barbe KM; Ritz N; Trück J; Fallegger A; Oberle SG; Martyn O; Wieser S
    Euro Surveill; 2024 Sep; 29(39):. PubMed ID: 39328156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk.
    Rietveld E; De Jonge HC; Polder JJ; Vergouwe Y; Veeze HJ; Moll HA; Steyerberg EW
    Pediatr Infect Dis J; 2004 Jun; 23(6):523-9. PubMed ID: 15194833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
    Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
    Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
    Simões EAF; Chirikov V; Botteman M; Kwon Y; Kuznik A
    J Infect Dis; 2020 Mar; 221(8):1256-1270. PubMed ID: 31165865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis.
    Zhang S; Akmar LZ; Bailey F; Rath BA; Alchikh M; Schweiger B; Lucero MG; Nillos LT; Kyaw MH; Kieffer A; Tong S; Campbell H; Beutels P; Nair H;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S680-S687. PubMed ID: 32227101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Gebretekle GB; Yeung MW; Ximenes R; Cernat A; Simmons AE; Killikelly A; Siu W; Rafferty E; Brousseau N; Tunis M; Tuite AR
    Vaccine; 2024 Aug; 42(21):126164. PubMed ID: 39079810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.